BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 193.8 SEK | -1.62% |
|
-1.82% | -27.63% |
| Apr. 15 | Nordic Shares Moved Upward Monday; Invisio Led Increases | DJ |
| Apr. 12 | Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest | DJ |
| Sales 2023 | 616M 56M | Sales 2024 * | 502M 45.68M | Capitalization | 17.12B 1.56B |
|---|---|---|---|---|---|
| Net income 2023 | 229M 20.82M | Net income 2024 * | 16M 1.45M | EV / Sales 2023 | 37.4 x |
| Net cash position 2023 | 607M 55.15M | Net cash position 2024 * | 838M 76.15M | EV / Sales 2024 * | 32.4 x |
| P/E ratio 2023 |
103
x | P/E ratio 2024 * |
974
x | Employees | 88 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 44.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioArctic AB
More press releases
More news
| 1 day | -1.62% | ||
| 1 week | -1.82% | ||
| Current month | -10.03% | ||
| 1 month | -11.43% | ||
| 3 months | -17.74% | ||
| 6 months | -21.98% | ||
| Current year | -27.63% |
1 week
189.30
216.40
1 month
189.30237.60
Current year
189.30288.40
1 year
189.30392.00
3 years
66.70392.00
5 years
47.00392.00
10 years
20.40392.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 14-01-26 | |
| Founder | 77 | 03-01-23 | |
| Founder | 75 | 03-01-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eugen Steiner
CHM | Chairman | 70 | 16-12-31 |
| Director/Board Member | 58 | 23-05-31 | |
| Director/Board Member | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.25% | 5 M€ | +5.20% | ||
| 0.89% | 16 M€ | -8.26% | ||
| 0.25% | 148 M€ | +4.52% | - | |
| 0.19% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 193.8 | -1.62% | 127,850 |
| 24-04-17 | 197 | -3.34% | 150,144 |
| 24-04-16 | 203.8 | +0.69% | 136,063 |
| 24-04-15 | 202.4 | -5.33% | 258,332 |
| 24-04-12 | 213.8 | +8.31% | 952,585 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT
More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-05-17
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
193.8
SEK
Average target price
366.2
SEK
Spread / Average Target
+88.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.63% | 1.57B | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- BIOA B Stock
